Antihypertensive agents, insulin sensitivity, and new-onset diabetes

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 191-199

  Sarafidis, Pantelis A ^a   McFarlane, Samy I ^b   Bakris, George L ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CELIPROLOL; CILAZAPRIL; DILEVALOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LERCANIDIPINE; METOPROLOL; NIFEDIPINE; NISOLDIPINE; PLACEBO; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETOGENESIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MEDICAL RESEARCH; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; REVIEW; SYSTEMATIC REVIEW;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE;

EID: 34250745189     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0031-5     Document Type: Review

References (75)

1. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
2. Sarafidis PA, McFarlane SI, Bakris GL: Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep 2006, 6:219-224.
3. Bakris GL: The importance of blood pressure control in the patient with diabetes. Am J Med 2004, 116(suppl 5A):30S-38S.
4. Sarafidis PA, Nilsson PM: The metabolic syndrome: a glance at its history. J Hypertens 2006, 24:621-626.
5. National Diabetes Information Clearinghouse: Diabetes Statistics. Bethesda, MD: National Institutes of Health, NIH publication 02-3892; 2000.
6. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
7. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
8. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:1714-1721.
9. Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:646-653.
10. Sarafidis PA, Bakris GL: Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care 2006, 29:1167-1169.
11. Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991, 14:203-209.
12. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
13. Lind L, Berne C, Pollare T, Lithell H: Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995, 9:137-141.
14. Prince MJ, Stuart CA, Padia M, et al.: Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med 1988, 148:2363-2368.
15. Harper R, Ennis CN, Sheridan B, et al.: Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994, 309:226-230.
16. Harper R, Ennis CN, Heaney AP, et al.: A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995, 38:853-859.
17. Grassi G, Seravalle G, Dell'Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
18. Hunter SJ, Wiggam MI, Ennis CN, et al.: Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive type 2 diabetic patients: a double-blind crossover study. Diabet Med 1999, 16:482-487.
19. Sarafidis PA, Bakris GL: Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich) 2006, 8:351-356.
20. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992, 1:92-101.
21. Pollare T, Lithell H, Morlin C, et al.: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989, 7:551-559.
22. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157.
23. Haenni A, Lithell H: Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994, 43:455-461.
24. Malminiemi K: Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995, 9:295-304.
25. Jacob S, Rett K, Wicklmayr M, et al.: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489-494.
26. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955-959.
27. Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
28. Mason RP, Kalinowski L, Jacob RF, et al.: Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005, 112:3795-3801.
29. Poirier L, Cleroux J, Nadeau A, Lacourciere Y: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001, 19:1429-1435.
30. Kaiser T, Heise T, Nosek L, et al.: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006, 24:1397-1403.
31. Sarafidis PA, Bakris GL: Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens 2007, 25:249-252.
32. Jauch KW, Hard W, Guenther B, et al.: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987, 17:448-454.
33. Lefkos N, Efthimiadis A, Liatsis I, et al.: Hemodynamic and biochemical changes after chronic administration of cilazapril to hypertensive patients. Cardiology 1993, 82:249-258.
34. Suzuki M, Ikebuchi M, Yokota C, et al.: Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens 1995, 17:1257-1268.
35. Zebekakis P, Kopras A, Lasaridis AN, et al.: A comparative study of the effects of amlodipine and fosinopril on blood pressure and insulin sensitivity in hypertensive patients [abstract]. J Hypertens 2003, 21:S71.
36. Seghieri G, Yin W, Boni C, et al.: Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Diabet Med 1992, 9:732-738.
37. Andersson PE, Lithell H: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996, 9:323-333.
38. Lender D, Arauz-Pacheco C, Breen L, et al.: A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999, 12:298-303.
39. Reneland R, Alvarez E, Andersson PE, et al.: Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000, 14:175-180.
40. Koyama Y, Kodama K, Suzuki M, Harano Y: Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002, 15:927-931.
41. Sarafidis PA, Lasaridis AN, Hatzistavri L, et al.: The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev Clin Pharmacol Pharmacokinet (International Edition) 2004, 18:60-66.
42. Benndorf RA, Rudolph T, Appel D, et al.: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006, 55:1159-1164.
43. Widimsky J, Sirotiakova J: Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Curr Med Res Opin 2006, 22:1287-1294.
44. Lind L, Berne C, Pollare T, Lithell H: Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. J Intern Med 1994, 236:37-42.
45. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
46. Haenni A, Lithell H: Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999, 17:S29-S35.
47. Kurtz TW: New treatment strategies for patients with hypertension and insulin resistance. Am J Med 2006, 119:S24-S30.
48. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
49. Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels: a systematic review. Blood Press 2006, 15:135-150.
50. Vitale C, Mercuro G, Castiglioni C, et al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005, 4:6.
51. Erbe DV, Gartrell K, Zhang YL, et al.: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pbarmacol 2006, 45:154-162.
52. Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065-1070.
53. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
54. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
55. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
56. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [no authors listed]. JAMA 2002, 288:2981-2997.
57. Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
58. Reid CM, Johnston CI, Ryan P, et al.: Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study [abstract]. Am J Hypertens 2003, 16(suppl):11A.
59. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
60. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
61. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
62. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
63. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255-3264.
64. Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004, 27:247-255.
65. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
66. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
67. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
68. Wilhelmsen L, Berglund G, Elmfeldt D, et al.: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987, 5:561-572.
69. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
70. Kjeldsen SE, Julius S, Mancia G, et al.: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006, 24:1405-1412.
71. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563-1574.
72. Bakris G, Molitch M, Hewkin A, et al.: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006, 29:2592-2597.
73. Bosch J, Yusuf S, Gerstein HC, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
74. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
75. Kostis JB, Wilson AC, Freudenberger RS, et al.: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.